Digitalizing pulmonary rehabilitation using a smartphone app is feasible in the management of chronic obstructive pulmonary disease, with patients completing a 20-day core programme showing improvements in health-related quality of life, according to a study.
Combination therapy with inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) can be safely escalated to triple therapy in the management of patients with chronic obstructive pulmonary disease (COPD), a meta-analysis suggests. Specifically, adding a long-acting muscarinic receptor antagonist (LAMA) to the combination poses no major risk to increase cardiovascular serious adverse events.
Cognitive behavioural therapy (CBT) intervention delivered by respiratory nurses is effective in reducing anxiety symptoms and utilisation of healthcare resources in patients with chronic obstructive pulmonary disease (COPD), thus providing a cost-effective strategy for treating anxiety — a symptom often comorbid with COPD, according to a study.
Long-term consumption of fruits, but not vegetables, appears to be associated with a reduced risk of developing chronic obstructive pulmonary disease, according to data from the prospective Swedish Mammography Cohort study.
Adding targeted lung denervation to drug therapy more than halves the rate of adverse respiratory events compared with drug therapy alone in patients with persistent chronic obstructive pulmonary disease (COPD), according to the AIRFLOW*-2 trial presented at ERS 2018.
A majority of health care professionals (HCPs) have poor knowledge of proper inhaler technique, which may prevent them from effectively teaching patients the correct use of inhalers that is important for effective therapy delivery, reveals a systematic review of 55 studies.
A recent study has enumerated the following features that characterize patients treated in the emergency department (ED) for acute exacerbation of chronic obstructive pulmonary disease (AECOPD): they commonly arrive by ambulance, have a high admission rate and have significant in-hospital mortality.
A combined triple therapy comprising fluticasone furoate (an ICS*), umeclidinium (a LAMA**), and vilanterol (a LABA***) in a single inhaler significantly lowers the rate of moderate or severe exacerbations compared with dual therapies of either ICS-LABA or LAMA-LABA in patients with symptomatic chronic obstructive pulmonary disease (COPD) and a history of exacerbations, the IMPACT# study shows.
Aclidinium bromide does not increase the risk of major adverse cardiac event (MACE) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) who also had significant cardiovascular (CV) risk factors, according to the phase IV ASCENT COPD* study presented at ATS 2018.